Sen­sei and In­stil Bio let go large chunks of work­forces, shift pipelines

Clin­i­cal tri­al dis­ap­point­ments have led Sen­sei Bio­ther­a­peu­tics and In­stil Bio to lay off 40% and 60% of em­ploy­ees, re­spec­tive­ly.

A tri­al flop on its lead pro­gram, push­back from a Ger­man bil­lion­aire stock­hold­er and a mas­sive stock slide pre­cede the pipeline makeover at Sen­sei. The biotech had 44 full-time work­ers as of Nov. 1 and will shut­ter its Boston re­search site, lead­ing to 17 work­ers let go.

With the fo­cus turned to a pre­clin­i­cal as­set, the biotech will keep the lights on at a Rockville, MD re­search fa­cil­i­ty and a small Boston busi­ness of­fice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER